Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,974 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06682780RecruitingPhase 1/Phase 2
Testing LM-2417 for advanced solid tumors
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07539285RecruitingPhase 1
HDM2024 treatment for advanced solid tumors
This study tests a new cancer drug called HDM2024 in people with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have stopped responding to standard treatments. The drug is designed to target specific proteins called EGFR and HER3 on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06672185RecruitingPhase 1
ARC101 for advanced Claudin-6 positive solid tumors
This trial tests a new drug called ARC101 for people with advanced solid tumors that are Claudin-6 positive. It aims to see if the drug is safe and can help shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06656624RecruitingPhase 2
Ribociclib plus hormone therapy for advanced breast cancer
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Nanjing, JiangsuAges 18–99 - NCT06937957RecruitingPhase 1
BR111 for advanced cancers
This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.
Shanghai, Pudong New AreaAges 18 years+ - NCT06658353RecruitingPhase 3
Study of VC004 for advanced solid tumors
This trial tests a new drug called VC004 for people with advanced solid tumors that have spread. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 12 years+ - NCT06625593RecruitingPhase 1
Study of BG-C137 for advanced solid tumors
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06618651RecruitingPhase 1
Study of SHR-3821 for advanced solid tumor cancers
This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Chengdu, SichuanAges 18–75 - NCT07527026RecruitingPhase 2
Camrelizumab and chemotherapy with radiation for advanced rectal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab) with chemotherapy and radiation to shrink advanced rectal cancer before surgery. The goal is to help more patients have successful surgery with complete tumor removal.
Beijing, Beijing MunicipalityAges 18–75 - NCT06605222RecruitingPhase 1/Phase 2
Testing SHR-7787 for advanced solid tumors
This trial is testing an investigational drug called SHR-7787 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if it is safe and how well it works. It may be an option if your tumor type is no longer responding to other treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06595108Recruiting
Targeted therapy and radiation for advanced liver cancer
This trial tests a combination of immunotherapy (atezolizumab), targeted therapy (bevacizumab), and targeted radiation for advanced liver cancer that cannot be surgically removed. The goal is to see if this approach helps control the cancer.
Yongin-siAges 19–80 - NCT07395479RecruitingEarly Phase 1
CAR-T therapy study for advanced blood and solid cancers
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05414032RecruitingPhase 2
Using leftover DNA signals to guide treatment after head and neck cancer
This Phase 2 trial tests a drug strategy for people with locally advanced head and neck cancer linked to HPV status. It looks at “molecular residual disease” by measuring tumor DNA in blood and uses early response and tumor test results to see who may benefit.
TorontoAges 18 years+ - NCT06543056RecruitingPhase 2
ES014 for advanced solid tumors
This study tests a new drug called ES014 for people with advanced solid tumors that can't be removed or have spread. It's an early trial to see if ES014 is safe and helps fight certain cancers.
BeijingAges 18 years+ - NCT07455734RecruitingPhase 1/Phase 2
Testing BNT3214 for advanced solid tumors
This trial tests an experimental drug, BNT3214, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if BNT3214 is safe and helps shrink tumors.
ClaytonAges 18 years+ - NCT05144152Recruiting
Testing M3 and FIT to predict polyp return in colon exams
This study checks how well two lab tests (M3 and FIT) can predict whether advanced colon polyps (adenomas) will come back. If you’ve had adenomas found on a prior colonoscopy, these results may help plan future surveillance.
Shatin, New TerritoriesAges 18 years+ - NCT05993234Recruiting
Trastuzumab deruxtecan for advanced HER2-positive stomach cancer
This study looks at a treatment called T-DXd (trastuzumab deruxtecan) for people with advanced stomach or gastroesophageal junction cancer that is HER2-positive and has been previously treated with trastuzumab. It also follows people receiving standard therapies to compare results.
KlagenfurtAges 18 years+ - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT07737509Recruiting
Understanding genetic factors in advanced solid tumor treatment
This study collects and analyzes tumor samples from people with advanced solid cancers to understand why some treatments work better than others and why resistance can develop. It aims to improve future treatments for patients like you.
SuttonAges 18 years+ - NCT06512428RecruitingPhase 2
Simmitinib plus irinotecan for advanced esophageal cancer
This trial tests a new combination of two drugs—simmitinib (a targeted therapy) and irinotecan (a chemotherapy)—for people with advanced esophageal cancer that has stopped responding to one prior treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Heilongjiang, HarbinAges 18–70 - NCT06302426RecruitingPhase 1
Testing INI-4001 for advanced solid tumors
This trial tests a new drug, INI-4001, for people with advanced solid tumors that have spread or can't be removed. It aims to see if the drug is safe and effective.
Albury, New South WalesAges 18 years+ - NCT06302062RecruitingPhase 1
Using lymph node T cells for advanced solid tumors
This trial tests a new treatment using T cells taken from your lymph nodes to fight advanced solid tumors that have not responded to standard therapies. The goal is to see if this approach can help shrink tumors or slow their growth.
Guangzhou, GaungdongAges 18–75 - NCT06500676RecruitingPhase 1/Phase 2
A study of GFH375 for KRAS G12D mutated solid tumors
This trial tests a new oral medication (GFH375) for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the drug can shrink tumors or slow cancer growth.
Hefei, AnhuiAges 18–75
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,974 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.